The 340B program was created to help vulnerable and uninsured patients access needed medicines. However, the program continues to grow exponentially without appropriate guardrails, putting it at risk. Appropriate oversight and reform is needed to ensure the 340B program can fulfill its promise to patients.
This week the Alliance for Integrity and Reform of 340B (AIR340B), of which PhRMA is a member, released a new paper looking at contract pharmacy arrangements in the 340B program. This paper follows an earlier AIR340B analysis that revealed shockingly low levels of charity care provided at 340B hospitals. Compared to many clinics across the country that are truly serving high volumes of uninsured Americans, some hospitals seem to have deviated off course.
For more, check out PhRMA CEO John Castellani’s column today in The Morning Consult on the 340B program. PhRMA is committed to strengthening the program to ensure it helps vulnerable and uninsured patients as intended.
Allyson Funk Ally is a former senior director of public affairs at PhRMA focused on advocacy issues for the biopharmaceutical industry. Her expertise includes Medicare, Medicaid, 340B, health reform and more. Prior to PhRMA, her experience included leading health communications for a large membership organization, supporting public affairs clients and working for the governor of Louisiana.